Huadong Medicine reports strong Q3 2025 earnings growth

Huadong Medicine announced a 7.71% increase in net profit attributable to shareholders, reaching 933.09 million yuan for Q3 2025. The company's total operating income rose by 4.53% to 10.99 billion yuan for the quarter. Year-to-date (YTD) figures also showed positive trends, with a 3.77% increase in operating income to 32.66 billion yuan and a 7.24% rise in YTD net profit attributable to shareholders, totaling 2.75 billion yuan.

The pharmaceutical industrial segment, particularly its core subsidiary Sino-US Huadong, reported an 11.10% increase in operating income to 11.05 billion yuan and a 15.62% rise in net profit to 2.48 billion yuan for the first nine months of 2025. Innovative products contributed significantly, with sales and agency service income totaling 1.68 billion yuan, up 62% year-on-year. Notably, the anti-cancer drug somatostatin injection (Ailaxian) generated over 45 million yuan in sales from January to September 2025.

The company also expanded its pipeline with the approval of several new drugs and medical devices, including the global first-in-class Remabiprazine injection (development code: MB-102) in October 2025. Additionally, the medical aesthetics sector achieved 1.57 billion yuan in operating income for the first nine months of 2025.